Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 11/20 | 0.49 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6168378 | 0.88 | PTGS2 (0.51) | PTGS2PTGS1MIFPDE3A | |
| SCHEMBL6309912 | 0.87 | PTGS2 (0.47) | PTGS2PTGS1CDK2 | |
| SCHEMBL6168610 | 0.87 | PTGS2 (0.51) | PTGS2PTGS1PDE3A | |
| SCHEMBL6168801 | 0.86 | PTGS2 (0.55) | PTGS2PTGS1CDK2 | |
| SCHEMBL6170005 | 0.86 | PTGS2 (0.50) | PTGS2PTGS1PDE3ACDK2 | |
| SCHEMBL6171523 | 0.85 | PTGS2 (0.54) | PTGS2PTGS1CDK2 | |
| SCHEMBL6309185 | 0.84 | PTGS2 (0.48) | PTGS2PTGS1CDK2 | |
| SCHEMBL6170748 | 0.84 | PTGS2 (0.55) | PTGS2PTGS1 | |
| SCHEMBL6170018 | 0.83 | PTGS2 (0.52) | PTGS2PTGS1CDK2 | |
| SCHEMBL6180126 | 0.83 | PTGS2 (0.49) | PTGS2PTGS1PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1528059-A2 | Substituted isoxazoles for the treatment of inflammation | G.D. Searle LLC (US) | 2005-05-04 | — | — | EP | claimed |
| EP-0809636-B1 | SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2002-09-04 | — | — | EP | claimed |
| EP-1223167-A2 | Substituted isoxazoles for the treatment of inflammation | G.D. Searle & Co. (US) | 2002-07-17 | — | — | EP | claimed |
| EP-0809636-A1 | SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-12-03 | — | — | EP | claimed |
| US-5633272-A | Substituted isoxazoles for the treatment of inflammation | PHARMACIA & UPJOHN COMPANY LLC | 1997-05-27 | — | — | US | claimed |
| WO-1996025405-A1 | SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-08-22 | — | — | WO | claimed |
| US-20080293679-A1 | Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of COX inhibitors | CARDAX PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20060167075-A1 | Modulators of FAAH | IRONWOOD PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | disclosed |
| EP-1528059-A2 | Substituted isoxazoles for the treatment of inflammation | G.D. Searle LLC (US) | 2005-05-04 | — | — | EP | disclosed |
| EP-0809636-B1 | SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-1223167-A2 | Substituted isoxazoles for the treatment of inflammation | G.D. Searle & Co. (US) | 2002-07-17 | — | — | EP | disclosed |
| US-5985902-A | TREATING INFLAMMATION AND INFLAMMATION-ASSOCIATED DISORDERS, SUCH AS ARTHRITIS | G.D. SEARLE & CO. (US) | 1999-11-16 | — | — | US | disclosed |
| US-5859257-A | ANTIINFLAMMATORY, ANTIARTHRITIC AGENTS | G. D. SEARLE & CO. (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0809636-A1 | SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-12-03 | — | — | EP | disclosed |
| US-5633272-A | Substituted isoxazoles for the treatment of inflammation | PHARMACIA & UPJOHN COMPANY LLC | 1997-05-27 | — | — | US | disclosed |
| WO-1996025405-A1 | SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293679-A1 | Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of COX inhibitors | LPL, ALOX12, LCLAT1 | PTGS2 9/4885PTGS1 26/4885MIF 1133/4885 |
| US-20060167075-A1 | Modulators of FAAH | FAAH, FAAH2, HCRTR2 | PTGS2 107/4885PTGS1 73/4885MIF 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.